High urine IP-10 levels associate with chronic HCV infection

Petrone, Linda; Chiacchio, Teresa; Vanini, Valentina; Petruccioli, Elisa; Cuzzi, Gilda; Giacomo, C. Di; Pucci, Luigia; Montalbano, Marzia; Lionetti, Raffaella; Testa, Angela; Lapa, Daniele; Navarra, Assunta; Visco-Comandini, Ubaldo; Goletti, Delia

doi:10.1016/j.jinf.2014.02.008

Cited by 28 publications

(23 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To highlight the role of IP-10 in HCV infection pathogenesis Serum level of IP-10 in patient group with high level of liver enzyme, was upper than people with normal level of liver enzyme and if the fibrosis level was considered, we had found stronger correlation between IP-10 and fibrosis level. These results were according to Petron study showing the correlation of IP-10 level with fibrosis as well as liver cytolysis (28). Reiberger showed also in 2008 in Australia that IP-10 level correlate with liver enzyme level such that serum level of IP-10 in patient group with high level enzyme was higher than people with normal level of liver enzyme in consistent with our study (32).…”

Section: Discussionsupporting

confidence: 92%

“…Serum and urine levels of IP-10 in people with HCV infection was upper than healthy people and IP-10 level in serum was upper than urine one according to previous studies (26,27). Consistent with this, in one study done by Petrone in 2014 in Italy, it was shown serum level of IP-10 being higher than urine level and also serum and urine levels of IP-10 in people with HCV infection was significantly higher than healthy (28). Also in Johansson study in 2015 in USA, it was shown that serum level of IP-10 was higher than healthy people (29).…”

Section: Discussionsupporting

confidence: 76%

See 1 more Smart Citation

Serum and Urine Level of IP-10 in Patients with HCV infection Based on Clinical and Virological Markers

2015

View full text Add to dashboard Cite

Background and Aims: IP-10 molecule is a new biomarker to predict response to treatment in chronic HCV infection. Also urine IP-10 has been suggested as a biomarker in other infections. But already, it has low data in urine as well as serum level of IP-10 for HCV infection. The aim of this study was to assess urine and serum level of IP-10 in patients with type 1 and 3a HCV infection. Materials and Methods:In this case-control study, 105 patients with HCV infection were involved in three 35 people groups. Blood and urine sample of all patients was collected to determine IP-10 level. Finally, data analysis was reported using SPSS, mean statistics analysis and T test. Results: The age mean was 41.611.2 ranging 21-68. Urine and serum level of IP-10 in patient group was significantly higher than control (p=0.001). Serum level of IP-10 based on HCV genotype was higher significantly in genotype 1a than 3a (p=0.001) but there was no significant difference of urine IP-10 level between genotypes 1a and 3a. Conclusions:The results show IP-10 is a proper marker to determine the prognosis of fibrosis and progress liver inflammation and on the other hand, the prediction of response to treatment differs in various genotypes of HCV infection.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionsupporting

confidence: 76%

Serum and Urine Level of IP-10 in Patients with HCV infection Based on Clinical and Virological Markers

2015

View full text Add to dashboard Cite

show abstract

“…Interestingly, IP‐10 was also detected in the urine of adult patients and Ugandan children with active TB, and IP‐10 levels decreased following efficacious therapy . As has been recently suggested, however, IP‐10 should probably be considered as a marker of general inflammation …”

Section: Bm For Diagnosing Active Tbmentioning

confidence: 76%

Update on tuberculosis biomarkers: From correlates of risk, to correlates of active disease and of cure from disease

et al. 2018

Self Cite

View full text Add to dashboard Cite

Tuberculosis (TB) remains a devastating disease, yet despite its enormous toll on global health, tools to control TB are insufficient and often outdated. TB Biomarkers (TB-BM) would constitute extremely useful tools to measure infection status and predict outcome of infection, vaccination or therapy. There are several types of TB-BM: Correlate of Infection; Correlate of TB Disease; Correlate of Increased Risk of Developing Active TB Disease; Correlate of the Curative Response to Therapy; and Correlate of Protection (CoP). Most TB-BM currently studied are host-derived BM, and consist of transcriptomic, proteomic, metabolomic, cellular markers or marker combinations ('signatures'). In particular, vaccine-inducible CoP are expected to be transformative in developing new TB vaccines as they will de-risk vaccine research and development (R&D) as well as human testing at an early stage. In addition, CoP could also help minimizing the need for preclinical studies in experimental animals. Of key importance is that TB-BM are tested and validated in different well-characterized human TB cohorts, preferably with complementary profiles and geographically diverse populations: genetic and environmental factors such as (viral) coinfections, exposure to non-tuberculous mycobacteria, nutritional status, metabolic status, age (infants vs children vs adolescents vs adults) and other factors impact host immune set points and host responses across different populations. In this study, we review the most recent advances in research into TB-BM for the diagnosis of active TB, risk of TB development and treatment-induced TB cure.

show abstract

“…Urine is a noninvasive sample source that is relatively time and cost efficient . Particularly for newborns, children, and patients requiring repeated sampling to monitor antiviral therapy efficacy, urine has remarkable advantages over blood, including noninvasive sampling, convenient collection, and low biological risk to clinical staff . Several studies have reported HCV RNA detection in the urine of patients with hepatitis C, although with varying success, reporting detection rates of 0% to 56.5% .…”

Section: Introductionmentioning

confidence: 99%

“…15 Particularly for newborns, children, and patients requiring repeated sampling to monitor antiviral therapy efficacy, urine has remarkable advantages over blood, including noninvasive sampling, convenient collection, and low biological risk to clinical staff. [16][17][18] Several studies have reported HCV RNA detection in the urine of patients with hepatitis C, although with varying success, reporting detection rates of 0% to 56.5%. [19][20][21][22] However, the underlying mechanism of HCV RNA shedding in urine and in what form it is present in urine remains unclear.…”

Section: Introductionmentioning

confidence: 99%

Quantitative detection of hepatitis C virus RNA in urine of patients with chronic hepatitis C using a novel real‐time PCR assay

Han

Zhang

et al. 2018

Journal of Medical Virology

View full text Add to dashboard Cite

Hepatitis C virus (HCV) RNA can be detected in body fluids such as urine. However, because of deficiencies in established isolation and detection methods, the actual prevalence and form of HCV RNA in the urine of patients with hepatitis C remain unclear. To more sensitively and accurately measure urine HCV RNA levels, a novel real-time PCR assay with a modified isolation method and short amplicon designed for short HCV RNA fragments was developed in this study. The limit of detection, precision, linearity, and specificity of the assay was evaluated and demonstrated high-quality performance. The prevalence of HCV RNA in the urine of viremic patients infected with HCV was 60% (36/60), as determined by a 62-bp assay. The HCV RNA detection rate and concentration were much lower with a 157-bp assay, and were undetectable with 222- and 304-bp assays. With the 62-bp assay, patients with detectable urine HCV RNA had significantly higher plasma HCV RNA levels ( P < 0.001), and plasma and urine concentrations were significantly positively correlated ( R = 0.708, P< 0.001). The method not only increased the detection rate of urine HCV RNA but also revealed the presence of short HCV RNA fragments in urine, indicating that urine from CHC patients with normal kidney function should not be infectious. In addition, it raised the possibility of urinary HCV RNA as a potential noninvasive marker for therapeutic monitoring of patients with hepatitis C.

show abstract

High urine IP-10 levels associate with chronic HCV infection

Cited by 28 publications

References 25 publications

Serum and Urine Level of IP-10 in Patients with HCV infection Based on Clinical and Virological Markers

Serum and Urine Level of IP-10 in Patients with HCV infection Based on Clinical and Virological Markers

Update on tuberculosis biomarkers: From correlates of risk, to correlates of active disease and of cure from disease

Quantitative detection of hepatitis C virus RNA in urine of patients with chronic hepatitis C using a novel real‐time PCR assay

Contact Info

Product

Resources

About